AUTHORS
Xiaoying Zhang, Jia Wei, MD, PhD2, Yang Cao, MD3, Jue Wang4, Yicheng Zhang5
AFFILIATIONS
1 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
4 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
5 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
ABSTRACT
Background:
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory diffuse large B-cell lymphoma, yet two-thirds of patients remain at risk of relapse or progression, with CD19-negative escape representing an important mechanism of resistance. Autologous stem cell transplantation (ASCT) followed by CAR T-cell infusion can produce durable remissions, suggesting that immune reconstitution may recruit antitumor responses. Conventional type 1 dendritic cells (cDC1s) specialize in cross-presenting tumor-derived antigens and priming endogenous T cells, but their contribution to sequential therapy remains unknown. We therefore sought to determine whether cDC1-dependent epitope spreading links ASCT-mediated immune reconstitution to the control of CD19-negative lymphoma.
Methods:
We established two immunocompetent syngeneic murine lymphoma models: CAR T-cell monotherapy (CAR T-only) and ASCT combined with CAR T-cell therapy (Sequential). Tumor growth and survival were monitored. Single-cell RNA sequencing and paired T-cell receptor sequencing (scRNA/TCR-seq) profiled the intratumoral immune landscape, and ELISPOT assays quantified endogenous T-cell reactivity. To test CAR-independent epitope spreading, mice bearing subcutaneous CD19-positive tumors in the left flank received the assigned treatment before contralateral challenge with CD19-negative cells. The requirement for cDC1 was examined by repeating the treatment comparison in Batf3−/− mice.
Results:
Sequential treatment conferred superior tumor control (P=0.006) and extended survival relative to CAR T-cell therapy alone. Single-cell transcriptomic profiling revealed broad remodeling of the tumor immune microenvironment, with reduced regulatory T cells, myeloid-derived suppressor cells, and Isg15-high macrophages, coupled with increased intratumoral cDC1 abundance and activation. cDC1s from Sequential tumors acquired a coordinated antigen-presentation state characterized by predominant upregulation of H-2 class II molecules, concurrent induction of H-2 class I molecules, and high expression of the MHC class II invariant chain Cd74. Gene-set enrichment revealed a shift from the interferon-response program that predominated after CAR T-cell therapy alone toward programs associated with antigen processing and presentation, granulocyte migration, and IL-1 signaling after Sequential treatment.
Sequential treatment exhibited a distinct distribution of T cell subsets, characterized by an increased proportion of CD8+ naïve T cells, reduced expression of CD8+ T cell exhaustion markers, and expansion of resident subsets (Cxcr6+ CD4+ T cells). Paired TCR-seq revealed that Sequential treatment selected or generated T cells with longer CDR3 regions, exhibited a bias toward specific paired TRAV-TRBV gene usage and increased overall TCR diversity, thereby enhancing antigen epitope spreading. Within the cytotoxic CD8+ T-cell compartment, low-expansion clonotypes were enriched and exhibited higher cytotoxicity and lower exhaustion scores, consistent with a broader, highly functional endogenous response. ELISPOT assays corroborated increased endogenous T-cell reactivity. Together, these findings demonstrate that Sequential treatment broadens the endogenous TCR repertoire and promotes epitope spreading.
Following contralateral challenge with CD19-negative cells, mice in the CAR T-only group developed progressive tumors, with a mean volume of approximately 150 mm³ on day 10, whereas no palpable lesions were detected in the Sequential group on day 10 (P=0.013). In Batf3−/− mice, Sequential treatment no longer conferred superior tumor control over CAR T-cell therapy alone (P=0.127), supporting a requirement for Batf3-dependent cDC1s in the control of CD19-negative disease.
Conclusions:
ASCT reprograms the tumor immune microenvironment to favor cDC1 accumulation and coordinated antigen presentation, thereby expanding a diverse, highly functional, and less exhausted endogenous T-cell repertoire capable of restraining CD19-negative lymphoma. The loss of therapeutic benefit in Batf3−/− mice identifies cDC1-dependent epitope spreading as a key mechanism linking ASCT-mediated immune reconstitution to durable CAR T-cell activity. These findings highlight cDC1s as central orchestrators of CAR-independent antitumor immunity and provide a mechanistic rationale for ASCT-based strategies to overcome antigen escape.
DISCLOSURES
Xiaoying Zhang: No relevant conflicts of interest to declare.